Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by schocoron Dec 18, 2020 5:49pm
147 Views
Post# 32145394

RE:Gud will miss out on the "psychedelics" like Goodman missed

RE:Gud will miss out on the "psychedelics" like Goodman missed
bbzzzz wrote: out on the "MJ" stocks . Actually what has Gud taken advantage of besides being a great tax loss equity for the past few Decembers .

 If a news release about anything to do with the shroom sector came out by Gud ,it would propel this P>O>S into something tangible . Yes , there is merit to the psychedelics being very helpful to the mental health problems of the world . See mmed , trip , buzz , myco .....do your own DD .
All these firms are sucking up Gud's lunch ....

 Looking to exit or take a shroom trip ......


I view this as a very silly post. You want a medical company that specializes in obscure treatments not yet licensed in Canada to branch out to the over crowed shroom market? Than you state that the company MISSED the MJ sector? Really? What did they miss out on there? If you want exposure to those shroom or MJ stocks there are literally DOZENS of companies you can invest in - but instead you begrudge management for not hoping on the bandwagon when you can easily do it yourself.
<< Previous
Bullboard Posts
Next >>